Clinical Trial Update: TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TPC plus Cadonilimab versus TPC alone in anti-PD-1 resistant recurrent or metastatic nasopharyngeal carcinoma; the study is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Cadonilimab
• TPC

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Cancinoma (NPC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING